Provided by Tiger Trade Technology Pte. Ltd.

United Therapeutics

515.46
-12.4500-2.36%
Post-market: 515.460.00000.00%19:30 EDT
Volume:266.87K
Turnover:138.11M
Market Cap:22.11B
PE:18.44
High:530.50
Open:527.94
Low:513.72
Close:527.91
52wk High:609.35
52wk Low:303.09
Shares:42.89M
Float Shares:39.35M
Volume Ratio:0.59
T/O Rate:0.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):27.95
EPS(LYR):27.86
ROE:19.31%
ROA:11.61%
PB:3.45
PE(LYR):18.50

Loading ...

United Therapeutics (UTHR) Will Present Phase 3 Data At European Congresses

Simply Wall St.
·
Yesterday

United Therapeutics Chairperson and CEO Martine Rothblatt Disposes of 7,500 Common Shares for $3.93 Million

Reuters
·
Aug 29

United Therapeutics Submits FDA NDA for PAH Drug Ralinepag

Reuters
·
Aug 28

RBC Capital Sticks to Its Buy Rating for United Therapeutics (UTHR)

TIPRANKS
·
Aug 27

United Therapeutics Chairperson, CEO Rothblatt Sells 9,500 Shares for $4.92 Million

Reuters
·
Aug 27

United Therapeutics Chairperson and CEO Martine A. Rothblatt Reports Disposal of Common Shares Worth $5,031,247.39

Reuters
·
Aug 25

Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR) and AdaptHealth (AHCO)

TIPRANKS
·
Aug 24

United Therapeutics Says FDA Accepts Ralinepag NDA for Pulmonary Arterial Hypertension

Reuters
·
Aug 24

United Therapeutics Corporation: Ralinepag Has not Been Approved for Use in Any Indication by FDA and Remains Investigational for Pah

THOMSON REUTERS
·
Aug 24

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

THOMSON REUTERS
·
Aug 24

United Therapeutics Corporation - FDA Sets Pdufa Target Action Date for Ralinepag on June 24, 2027

THOMSON REUTERS
·
Aug 24

United Therapeutics Chairperson, CEO Martine Rothblatt Disposes of 9,500 Common Shares for $5.01 Million

Reuters
·
Aug 21

United Therapeutics CEO Martine Rothblatt Disposes of 9,500 Shares for $4.79 Million

Reuters
·
Aug 19

United Therapeutics announces full enrollment in TETON-PPF study

TIPRANKS
·
Aug 17

United Therapeutics Seeks FDA Priority Review for Tyvaso Label Expansion in IPF

Reuters
·
Aug 17

United Therapeutics Corporation Announces Full Enrollment of the Teton-Ppf Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis

THOMSON REUTERS
·
Aug 17

United Therapeutics Corporation - Topline Data from Teton-Ppf Study Expected in Second Half of 2027

THOMSON REUTERS
·
Aug 17

United Therapeutics CEO Chair Martine Rothblatt Disposes of 9,500 Shares for $4.81 Million

Reuters
·
Aug 15

United Therapeutics Chairperson and CEO Martine Rothblatt Disposes of 8,500 Common Shares Worth $4.45 Million

Reuters
·
Aug 13

United Therapeutics CEO Chairperson Martine Rothblatt Disposes of 9,500 Shares Worth $5.03 Million

Reuters
·
Aug 11